Pfizer Investigational Site
Sheffield, S5 7AU, United Kingdom
NCT Number: NCT00674453
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
Looking for future studies?
Notify Me50 year and older
Female
Interventional
Phase 2
Sheffield, S5 7AU, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral tablet, 0.25 mg, daily, 2 years
Matching placebo tablet given once daily for 2 years
Time frame: 2 years
Time frame: 2 years
Ligand Pharmaceuticals
Industry
The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis
Acronym: LACE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06305156
Bone Diseases, Bone Diseases, Metabolic
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT02325414
Acute Spinal Cord Injury, Bone Diseases
Chicago, Illinois, United States
View Trial DetailsNCT01225055
Bone Diseases, Bone Diseases, Metabolic
Chicago, Illinois, United States
View Trial DetailsNCT04708886
Bone Diseases, Bone Diseases, Metabolic
Chicago, Illinois, United States
View Trial Details